SUO 2019: Response of FGFR3 Alterations In High-Grade Non-Muscle Invasive Bladder Cancer Treated with Intravesical BCG Therapy
SUO 2019 differential response of high grade non-muscle invasive bladder cancer to BCG on the basis of FGFR3 alterations.
Related Articles
AUA 2025: Upfront Cytoreductive Nephrectomy With Deferred Systemic Therapy For Metastatic Renal Cell Carcinoma
AUA 2025, Metastatic Renal Cell Carcinoma (mRCC), Upfront Cytoreductive Nephrectom, Upfront Cytoreductive Nephrectomy With Deferred Systemic Therapy For Metastatic Renal Cell Carcinoma, CARMENA trial,
AUA 2025: Performance of Minimal Residual Disease Detection with Urine-Derived DNA in High-Grade Bladder Cancer Patients Undergoing Recommended Repeat Transurethral Resection
AUA 2025 performance of minimal residual disease detection with urine-derived DNA, high-grade bladder cancer, recommended repeat TURBT, UroAmp.
AUA 2025: Evaluating the Heterogeneity of Advanced Prostate Cancer by 18F-DCFPyL and 18F-FDG PET/CT in a Prospective Cohort
AUA 2025, prostate cancer, 18F-DCFPyL, 18F-FDG PET/CT, Heterogeneity of Advanced Prostate Cancer by 18F-DCFPyL and 18F-FDG PET/CT, dual-tracer (¹⁸F-DCFPyL and ¹⁸F-FDG) PET/CT imaging.
AUA 2025: Phase II Study of Tislelizumab as Neoadjuvant Treatment for Cisplatin-Ineligible High Risk Upper Tract Urothelial Carcinoma
AUA 2025, upper tract urothelial carcinoma (UTUC), Tislelizumab, humanized IgG4 anti-PD-1 monoclonal antibody.
AUA 2025: Primary Resistance to Nivolumab plus Ipilimumab Therapy Affects Second-Line Treatment Outcomes in Patients with mRCC
AUA 2025, kidney cancer, renal cell carcinoma (RCC), metastatic renal cell carcinoma (mRCC), Nivolumab, Ipilimumab, Nivolumab plus Ipilimumab Therapy, sunitinib, Primary Resistance to Nivolumab plus…
AUA 2025: Impact of Timing of Recurrence on Survival Outcomes: Implications for Postoperative Management in a KEYNOTE-564 Population
AUA 2025 KEYNOTE-564 trial, clear cell renal cell carcinoma (ccRCC), adjuvant pembrolizumab, partial nephrectomy,
AUA 2025: Who Still Needs a Lymph Node Dissection with a Negative PSMA-PET? Results from the Michigan Urological Surgery Improvement Collaborative
AUA 2025 PSMA-PET imaging to stage men with prostate cancer, regional lymph node involvement, distant metastases, preoperative PSMA-PET imaging, Michigan Urological Surgery Improvement Collaborative (MUSIC),
AUA 2025: Prostate Cancer Risk Groups by PSMA-PET PROMISE (PPP): Results from an International Multi-Center Registry Study
AUA 2025, Prostate Cancer, Prostate Cancer Risk Groups by PSMA-PET PROMISE (PPP), Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography (PSMA-PET), PROMISE registry.
AUA 2025: Real-World Time-to-next-Treatment and Time-to-Castration-Resistance Among Patients with Metastatic Castration-Sensitive Prostate Cancer Using Androgen-Receptor Pathway Inhibitors with and Without Homologous Recombination Repair Alterations
AUA 2025, prostate cancer, metastatic castration-sensitive prostate cancer (mCSPC), androgen receptor pathway inhibitors (ARPIs), Homologous Recombination Repair (HRR), Homologous Recombination Repair Alterations, AMPLITUDE trial, TALAPRO-3…
AUA 2025: 225Ac-J591 PSMA-Targeted Radionuclide Therapy in Metastatic Castration-Resistant Prostate Cancer Patients with Prior 177Lu-PSMA Therapy
AUA 2025, Metastatic Castration-Resistant Prostate Cancer (mCRPC), 177Lu-PSMA Therapy, 225Ac-J591 PSMA-Targeted Radionuclide Therapy, 225Ac-J591 PSMA-Targeted Radionuclide Therapy in Metastatic Castration-Resistant Prostate Cancer Patients with Prior…